A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions-Reference-Cited by-同舟云学术

A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions

Published:2018-12 Issue:12 Volume:7 Page:1145-1152
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Pearson Steven D¹,Dreitlein William B¹,Towse Adrian²,Hampson Grace²,Henshall Chris²

Affiliation:

1. Institute for Clinical & Economic Review, Boston, MA, 02109, USA

2. Office of Health Economics, Southside, London, SW1E 6QT, UK

Abstract

Aim: To provide a framework for optimizing the development and use of real-world evidence (RWE) in drug coverage decisions. Materials & methods: The Institute for Clinical and Economic Review convened a Policy Summit with representatives from 23 payer and life science companies that compose the Institute for Clinical and Economic Review membership. Results: Summit participants helped refine a new conceptual framework that emphasizes the central role of contextual considerations and the evidentiary argument that the RWE is intended to support in designing the process for the development and interpretation of RWE. Conclusion: This framework may provide a structured way for pharmaceutical manufacturers and payers to develop a shared understanding of the best way to develop RWE that will ultimately be useful in informing coverage and formulary decisions.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2018-0059

Reference19 articles.

1. Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report

2. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?

3. Massachusetts Institute of Technology. MIT NEWDIGS Hosts Design Lab on Efficacy to Effectiveness (E2E) data and decision-making. https://newdigs.mit.edu/news/mit-newdigs-hosts-design-lab-efficacy-effectiveness-e2e-data-and-decision-making.

4. Patient-Centered Outcomes Research Institute. The Aspirin Study. http://theaspirinstudy.org/.

5. Center for Medical Technology Policy. Real-World Evidence Initiative Report. www.cmtpnet.org/green-park-collaborative/published-recommendations/real-world-evidence.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Up-front matching: an ongoing recruitment method for prospective observational studies that mimics randomization for selected baseline covariates;Journal of Biopharmaceutical Statistics;2024-07-22

2. Medication use evaluation of tocilizumab implementation in COVID-19 treatment guidelines: A causal inference approach;American Journal of Health-System Pharmacy;2024-06-03

3. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process;Journal of Pharmacy & Pharmaceutical Sciences;2024-02-28

4. Real-world data: A systematic literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process;2023-10-19

5. Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers;Value in Health;2023-04